We believe the training program should be individualized for each fellow since fellows come to the program with very different goals and
experiences. A strong effort is made to maintain maximum flexibility throughout the fellowship program.
Hematology/Oncology Early Oncology Drug Development Fellowship Program
A one-year training opportunity
in Early Oncology Drug Development is offered as part of the Pediatric
Hematology/Oncology Fellowship Program. We believe this new program constitutes
an important opportunity for fellows to garner training in early drug
development, which is a vital way to move the pediatric hematology/oncology
Program in Clinical Effectiveness
(PCE) at the Harvard T. H. Chan School of Public Health (HSPH)
The PCE is an intensive 15-credit
summer program that provides clinical investigators with fundamental training
in Clinical Epidemiology and Biostatistics. Fellows conducting clinical
research often take this course the summer after the first or second year of
fellowship training. Tuition for the course is fully funded by the training
program. For those who would like additional training, there are several
training grants available at Harvard that will cover the cost of the full
master’s program in public health.
We also offer single-year sub-fellowship clinical training
programs for those who seek additional training in each of the following areas:
Pediatric neuro-oncologyRequirements: Completion of pediatric hematology/oncology fellowship
Contact: Dr. Susan Chi, firstname.lastname@example.org,
617-632-4386Learn more: Pediatric neuro-oncology clinical
Stem cell (bone marrow) transplantRequirements: Completion of pediatric hematology/oncology fellowship
Contact: Dr. Leslie Lehmann, email@example.com,
Pediatric palliative careRequirements: Completion of general pediatrics residency
Contact: Dr. Joanne Wolfe, firstname.lastname@example.org,
U.S. News & World Report ranked Dana-Farber/Boston Children's the #1 pediatric cancer hospital in the nation.
More than 70 years ago, Dr. Sidney Farber refused to accept that childhood cancer was untreatable. His determination led to the development of chemotherapy and the first remissions of childhood leukemia.